Showing results (1101-1110 of 1,211) with videos related to

Sort By:
Pageof 122
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|January 29, 2026
Relative effectiveness of high-dose versus standard-dose influenza vaccine against hospitalizations and mortality according to Charlson Comorbidity Index: A post-hoc analysis of the DANFLU-1 randomized trialKatrine Feldballe Bernholm, Niklas Dyrby Johansen, Caroline Espersen, et al.
JACC. Heart Failure|June 12, 2025
Efficacy and Safety of Finerenone in Heart Failure With Preserved Ejection Fraction: A FINE-HEART AnalysisJohn W Ostrominski, Gerasimos Filippatos, Brian L Claggett, et al.
Diabetes Care|February 28, 2025
Efficacy and Safety of Finerenone in Type 2 Diabetes: A Pooled Analysis of Trials of Heart Failure and Chronic Kidney DiseaseJohn W Ostrominski, Brian L Claggett, Zi Michael Miao, et al.
JACC. Heart Failure|January 2, 2023
IGFBP-7 and Outcomes in Heart Failure With Reduced Ejection Fraction: Findings From DAPA-HFCarly Adamson, Paul Welsh, Kieran F Docherty, et al.
Circulation. Heart Failure|January 29, 2026
Finerenone, Liver Biomarkers, and Heart Failure With Mildly Reduced/Preserved Ejection Fraction: An Analysis of FINEARTS-HFJawad H Butt, Alasdair D Henderson, Pardeep S Jhund, et al.
European Heart Journal|May 23, 2023
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVERJawad H Butt, Toru Kondo, Mingming Yang, et al.
The New England Journal of Medicine|November 6, 2012
Strategies for multivessel revascularization in patients with diabetesMichael E Farkouh, Michael Domanski, Lynn A Sleeper, et al.
JACC. Heart Failure|June 20, 2025
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCMSara Saberi, Theodore P Abraham, Lubna Choudhury, et al.
JAMA Cardiology|November 12, 2023
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical TrialFinnian R Mc Causland, Brian L Claggett, Muthiah Vaduganathan, et al.
The Lancet. Diabetes & Endocrinology|December 2, 2021
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trialsPeter Rossing, Silvio E Inzucchi, Priya Vart, et al.
Pageof 122